Ariad Pharmaceuticals Inc. (Nasdaq: ARIA) continue to climb rattling strongly for a third-consecutive premarket session, on optimism for its AP24534 compound to impact chronic myelogenous leukemia in patients that were resistant to other drugs. While it is still not in late-stage trials, optimism remains that the company may be healthy to intend it there in the next year-and-a-half, effectively raise its pipeline. Shares are up 11 percent to $2.63 with more than 81,000 changing safekeeping as of 8:30 a.m. Eastern. — Mike Tarsala
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment